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Abstract
Background: The red tape and delays around research ethics and governance approvals frequently frustrate
researchers yet, as the lesser of two evils, are largely accepted as unavoidable. Here we quantify aspects of the
research ethics and governance approvals for one interview- and questionnaire-based study conducted in England
which used the National Health Service (NHS) procedures and the electronic Integrated Research Application
System (IRAS). We demonstrate the enormous impact of existing approvals processes on costs of studies, including
opportunity costs to focus on the substantive research, and suggest directions for radical system change.
Main text: We have recorded 491 exchanges with 89 individuals involved in research ethics and governance
approvals, generating 193 pages of email text excluding attachments. These are conservative estimates (e.g. only
records of the research associate were used). The exchanges were conducted outside IRAS, expected to be the
platform where all necessary documents are provided and questions addressed. Importantly, the figures exclude
the actual work of preparing the ethics documentation (such as the ethics application, information sheets and
consent forms). We propose six areas of work to enable system change: 1. Support the development of a broad
range of customised research ethics and governance templates to complement generic, typically clinical trials
orientated, ones; 2. Develop more sophisticated and flexible frameworks for study classification; 3. Link with
associated processes for assessment, feedback, monitoring and reporting, such as ones involving funders and
patient and public involvement groups; 4. Invest in a new generation IT infrastructure; 5. Enhance system capacity
through increasing online reviewer participation and training; and 6. Encourage researchers to quantify the
approvals processes for their studies.
Conclusion: Ethics and governance approvals are burdensome for historical reasons and not because of the nature
of the task. There are many opportunities to improve their efficiency and analytic depth in an age of innovation,
increased connectivity and distributed working. If we continue to work under current systems, we are perpetuating,
paradoxically, an unethical system of research approvals by virtue of its wastefulness and impoverished ethical
debate.
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Background
The gaze of scrutiny in the relationship between research
studies and Research Ethics Committees (REC), Institu-
tional Review Boards (IRB) and other bodies which grant
permissions for (funded) research to proceed is typically
unidirectional. Such organisations and their members
review research studies for the ethical, legal and govern-
ance issues they raise. Occasionally, roles are reversed:
research studies engage in probing and critical exploration
of the work of those gatekeepers. This paper represents
one such example. We build on existing literature and the
striking findings of an audit-type study of the ethics and
governance approvals of one of our recent projects (“Pre-
pared to Share?: a study of patient data sharing in complex
conditions and at the end of life” [1]) and offer proposals
for change.
The paper is structured as follows:
An introduction sets the scene of researchers’ attitudes
towards ethics and governance approvals processes.
We then present an extensive review of the empirical
and critical literature on RECs, IRBs and ethics and
governance approvals for health research (here under-
stood to include biomedical research, health services
research, and health-related research informed by the
behavioural and social sciences and the humanities). We
present a more detailed account of the background
literature than typical of an empirical paper, as the litera-
ture is dispersed and little known. We include scholarly
work which goes further than the mainstream storyline
around the ethical regulation of research, namely how
vital the work of ethics committees is to prevent a repe-
tition of, for instance, the Nazi atrocities in the name of
science, the Tuskegee syphilis experiment or experi-
ments like those of Milgram and Zimbardo. The publi-
cations that transcend this narrative do not (obviously)
question the need for ethical research, but probe into or
challenge the extent to which the current systems are
achieving that goal.
The respective scholarly field is far broader than appears
at first sight, yet it lacks both ‘self-awareness’ as a distinct-
ive area of study with core assumptions, questions, typical
methods, exemplar studies, etc. and meaningful visibility
to readers, at least outside the realm of bioethics. At the
same time the work of RECs, IRBs and other permissions
granting bodies affects all “human subjects research”. It is
an oft-forgotten determinant of the contents and bound-
aries of our scientific knowledge.
Following the literature review, we present our em-
pirical findings. These are from an audit-type study of
the ethics and governance approvals of a project on
patient data sharing at the end of life in a single lo-
cality in England. The trigger words of ‘data sharing’
and ‘end of life’ notwithstanding, this was, in the
words of a research governance officer, a “low-key”
(low-risk) study in terms of the ethical and govern-
ance issues it raised.
A further clarification of scope and terminology may
be helpful. Most of the background literature addresses
the ethics approvals of studies. However, study approvals
are a broader enterprise, variably termed (at least in the
UK) “research ethics and governance approvals”, “ethics
and R&D (research and development) approvals”, “study
assurances”, etc. Additional sign-offs are needed by R&D
departments of participating organisations or university
research offices (if the ethics approval has been granted
by a committee unattached to a university) around com-
pliance with regulations or the capacity of an organisa-
tion to host a project. Researchers involved in human
subjects research often use “ethics approvals” as a synec-
doche for this broader class of research ethics and govern-
ance approvals, not least because the latter are typically
contingent on the former and because the bulk of the
documentation is first prepared for the ethics review. Our
paper concerns this broader class of approvals.
Finally, we outline six proposals for change in the sys-
tems of ethics and governance approvals, with poten-
tially global application. Key features of these proposals
are that they emphasise the enrichment of the ethical
debate at least as much as the efficiency gains and that
they rely strongly on opportunities provided by the
growing sophistication and use of IT.
The negative set point of researchers’ expectations
Most researchers conducting human subjects research
soon internalise an emotional response to the REC/IRB
process and the broader system of research approvals.
While researchers variably like or dislike different phases
of a study, we are still to meet one looking forward to
ethics and governance approvals applications. More ac-
curately, we are still to meet a researcher mentioning
that they are about to embark on those processes with-
out pulling a face or changing their tone of voice. They/
we may latter comment that the process went smoothly,
was not as bad as expected, and was even quite useful.
In some cases, they/we may feel resentful about being
‘told’ what we can or cannot do when we think we ‘know
better’. For fully valid or rather suspect reasons, the set
point of researchers’ expectations of the ethics and gov-
ernance approvals for research studies is often remark-
ably negative.
This emotional response may be more local, less gen-
eralisable than it appears to us, fostered by the systems
and institutions we have been working in. We hope
readers will be willing to join a debate, both on the
scope of problems of research approvals and on new
solutions to them from a variety of perspectives and ex-
periences. It is, nonetheless, a sad state of affairs to be
experienced even in pockets of the academic world.
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First, in research as in daily life, ethical dilemmas (typic-
ally the starting point of approvals after research has
been funded) are amongst the most engaging and enli-
vening topics of conversation. Then, the people behind
the bureaucracy are often thoughtful, well-intentioned
individuals willing to make a difference to research and
research subjects. REC and IRB board members are
generally volunteers. Some of them are, or have been,
researchers themselves. Many members of staff working
on broader governance approvals, for instance in clinical
research networks, individual healthcare organisations or
universities, are consistently going the extra mile to sup-
port researchers in navigating complex systems. They
can easily introduce inordinate delays or even bring the
whole enterprise down if only ‘working to rule’ and
within the explicit remit of their (paid) roles.
Yet for many researchers with no insider experience in
such processes, ethics and governance approvals are
hardly ever about ethical deliberation and motivating
exchanges with people supporting you to conduct a bet-
ter study. More often than not, researchers experience
them as exercises of form filling; of engaging with a tire-
some and wasteful bureaucracy; of learning the rules
and language of a game and sticking with your pre-
scribed roles in it; and, more cynically, of somebody out
there caring about ethical conduct only insofar as litiga-
tion and reputational damage can be avoided. As a re-
sult, many of us working in areas or with methods that
may be “exempt” from REC/IRB review would consider
fitting a study into an exempt category and avoiding the
process altogether, while upholding ethical research
standards as an integral part of taking professional re-
sponsibility (more or less successfully).
Such impressionistic accounts of researchers’ discon-
tent are borne out by formal studies. In a survey of so-
cial researchers working on health and applying for NHS
ethics approval (UK system under the National Health
Service), Richardson and McMullan [2] found that 78%
of their respondents (101) agreed or strongly agreed that
the time for preparing an application inhibited social
research in health and 75% (98) either disagreed or
strongly disagreed that the amount of paperwork re-
quired was reasonable. Over half (51%, 64 individuals)
reported they had modified their research design for the
worse in order to secure ethical approval; 45% (58) had
modified their research design to avoid the process; 30%
(40) had abandoned their research before applying and
12% (16) during the application process (though we
cannot assume that the ethics approval process was the
sole reason). Twenty-one percent (26) revised their re-
search design after obtaining approval and did not seek
further permissions. Fifteen percent (19) had started re-
search needing NHS research ethics approval without
applying and 12% (14) had commenced their research
before the formal approval was given. More positively,
32% (41) of respondents had made changes for the bet-
ter as a result of the ethics approval process [2].
Interestingly, for those of us who internalise such
negativism, this happens almost entirely through social-
isation in our research community and overlaying our
personal experiences on the socialisation process. We do
not learn to be critical of the ethics and governance
approvals of human subjects research by reading
academic and professional literature presenting critical
arguments or worrying empirical findings. Such litera-
ture is sparse, dispersed and hardly ever a syllabus item.
The sparse and fragmented literature on ethics and
governance approvals
To our knowledge, there are only two well-known
book-length critical explorations of IRBs (with the popu-
larity still confined to bioethics circles rather than those
of medical and health researchers): Zachary Schrag’s
Ethical Imperialism: Institutional Review Boards and the
Social Sciences, 1965–2009 (2010) [3] and Laura Stark’s
Behind Closed Doors: IRBs and the Making of Ethical
Research (2011) [4]. Schrag’s Ethical Imperialism
explores the regulation of research in the social sciences
and humanities by IRBs and how derivative this regulation
is of the concerns, ethical codes, rules and blueprints of
legislation and regulation pertaining to biomedical and, to
some extent, psychological research. It illustrates how
limited or unsuccessful the involvement of social scientists
in the debates was (with them practically “left howling
outside the door” and becoming “objects of policy rather
than its authors”, op.cit., p. 4, p. 8). As any good history
book, it shows the contingency of much of what we now
take for granted and ethical in human subjects research
(e.g. the very concept of prior/prospective review; the
risks-benefits framework; even the “do not harm”
principle once applied outside of patient populations, such
as in studies aiming to increase public accountability).
Much of the regulation wielding “totemic influence over
the practice of research ethics” (op. cit., p. 78) has also
been shaped by time and staff limitations; the moment-
to-moment availability or lack of particular types of ex-
pertise; by public and political pressures; by tactics and
personalities; by the supposedly neutral work of redrafting
and editing; by the gradualism of introducing changes,
which keeps them off the radar of those most affected by
them. Schrag’s book is an unlikely page-turner for work so
meticulous in tracing and representing historical detail, so
careful in crafting precise and information-dense sen-
tences, and so concerned with getting the history right as
opposed to advancing a righteous argument.
Published shortly after Schrag’s monograph, Laura
Stark’s Behind Closed Doors is an ethnographic study
(again from the US) based on observations of IRB
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meetings and interviews with IRB members, with some
elements of a historical exploration. The historical ac-
count focuses on the origins of the method for making
decisions about research ethics: group review by experts
required to reach a consensus. After over 60 years of
using this approach, it may appear to be the most reli-
able and overall ‘best’ way of making research ethics
decisions. Yet group reviews are also a consequence of a
particular historical configuration: IRBs are “direct
descendants of the Clinical Research Committee that
met inside NIH’s Clinical Center starting in the 1950s”
[op. cit., p. 157]. Stark also argues that rather than hav-
ing group review imposed on researchers by outsiders
(such as bioethicists or activists, as the story often goes),
it was primarily researchers and NIH leaders who devel-
oped, justified and expanded this mechanism “as a tech-
nique for promoting research and preventing lawsuits”
[op.cit., p. 8].
Core findings from Stark’s ethnographic work concern
the IRBs’ methods for making decisions. For example,
board members appeared to be reading “researchers’
application documents like tea leaves for signs of good
character” (p. 6). Most notably, the researcher’s apparent
attention to detail was translated into judgments of his
or her professional competence and trustworthiness (pp.
17–18). Board members used “warrants” to justify their
recommendations and although some pertained to mat-
ters of fact and professional expertise, a surprising num-
ber came from their private lives. The people who
featured there came to serve “as stand-ins for research
participants”, thus reinforcing the biases of IRB member-
ship (p. 14). IRBs typically invoked local precedents (p.
47 onwards) in their decision-making processes as
opposed to abstract ethical rules. This, Stark argued,
ensured efficiency and internal consistency of decisions
over time, but was also the source of the much-lamented
variability of decisions across IRBs. (Of course, we need
to acknowledge the critical stance of “Behind Closed
Doors”, meaning that it draws more attention to un-
acknowledged and problematic aspects of the system as
opposed to its strengths and good processes.)
The empirical and critical explorations of research
approvals in published papers have a rather limited over-
lap with the work of Scrhag and Stark. No relevant
literature review seems to have been conducted, whether
systematic or traditional. We offer a preliminary sum-
mary of key themes and approaches, with a focus on the
last 20 years.
“Horror stories” appear to be one of two main ‘genres’
in the literature, with the term first used by Bradford
Gray in 1978 of the “sad tales told by scholars in their
letters to the National Commission and in their testi-
mony at the IRB hearings of 1977” (p. 161) [3]. Mary
Dixon-Woods et al. call them “wounding encounters”
[5]. More neutrally, these are case studies of challenging
ethics review processes, due to time delays and incon-
sistencies of decisions across committees; [6–11] bur-
eaucracy, form filling, paperwork and over-concern with
minor language and grammar issues; [12–14] lack of
appropriate expertise, which may lead to inappropriate
rejections, criticisms and recommendations; [15] block-
ing of important research [16] or compromising its
rigour, e.g. through negative effects on recruitment [17].
Mounting costs are also a source of frustration. Most
strikingly, Kano et al. estimate personnel costs of obtain-
ing the 84 approvals for their multi-site project at
US$121,344 [18] (note, however, that the system for
multisite projects in the US has now changed).
Some of those publications are strongly emotionally
charged. Mentions of “horror stories” and “wounding
encounters” are also typical elements in polemical texts
of scathing criticism and radical dismissal of the value of
the existing systems of ethics review, especially if applied
outside of biomedicine, such as to social sciences
research (e.g. see Dingwall and to some extent Derby-
shire [19, 20]). Many publications describing significant
challenges, however, aim to remain objective and con-
structive, giving specific recommendations for improve-
ments rather than questioning the overall value of the
system.
There are also studies which, while arising from a back-
ground awareness of the challenges around ethics ap-
provals, go straight into exploring and evaluating models
for optimising the work involved. Recent research of this
type concerns, for instance, the introduction of an ethics
officer, [21] the use of structured tools to evaluate the
work of RECs/IRBs, whether through self-assessment or
researcher assessment, [22, 23] models for simplifying
standard operating procedures, [24] and approaches built
around specific conditions and enabling better separation
between the scientific and ethical appraisal within the
ethics review [25].
More broadly, audits and evaluations of RECs/IRBs,
typically survey-based, appear to be the other leading
genre in the literature. This may be a historical path
dependence dating back to 1975, when the National
Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research (the commission
which created most of the foundations for regulating
human subjects research) commissioned the original
survey of researchers and IRB members (see p. 63
onwards in Schrag [3]). In the last decade, topics include
the overall availability and profile (composition, arrange-
ments for their work, etc.) of IRBs and RECs, primarily
in areas where ethical regulation of research is new;
[26–32] comparisons of committee members’ and re-
searchers’ views on ethical issues in complex areas; [33–35]
practices, policies and requirements of IRBs/RECs; [36–38]
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committee members’ knowledge of and attitudes to
ethically and legally complex topics [39, 40] and re-
searchers’ perceptions of the review process, out-
comes and impact [2, 41, 42].
The literature described above makes little explicit use
of theory. In contrast, there is an identifiable niche of
work on ethics approvals drawing on theory from the
social sciences [5, 9, 43–45]. It problematises the foun-
dations of the new regimes of control and warns against
their dangers, particularly in the context of the social
sciences. Narrower topics are also explored. For in-
stance, Dixon-Woods et al. look into the social functions
of REC letters, including ‘stabilising “what is ethical” in a
world where ethical matters are in fact indeterminate’;
providing institutional displays of “care, thoroughness
and thoughtfulness”; and structuring the relationship
between the REC and applicants, reinforcing a ritualised
supplicant-authority relationship [5]. Or, against ex-
pectations that REC decision-making is yet another
impersonal process of a modern bureaucracy, Hedge-
coe argues that local knowledge, trust and “facework”
(roughly, the direct face-to-face interactions between
applicants and committee members which serve to build
trust) are surprisingly important for the decision-making
processes of local RECs [44].
Some recent trends in the literature can also be identi-
fied. There is a fast growing global dimension to it (see,
for instance, [46–49]; about a fifth of the 100 most
recent publications retrieved by “ethics research com-
mittees” as a major heading in PubMed, Jan 2018, were
from developing world countries or countries with
smaller research communities). There is also attention
to ethics approvals challenges and solutions for newer
or newly popular study types, such as participatory
research or co-design studies, [50–53] biospecimens
and biobanking studies, [54–56] digital health re-
search [57–59] and research in disaster and develop-
ing world contexts [60–65].
Finally, there are red threads of issues which do not
become the focus of texts but are picked and inter-
weaved in much of the critical literature. It often re-
minds us that ‘there is no single “right” answer to (most)
ethical issues’ (p. 795); [5] that what constitutes ethics,
ethical practice and ethical decisions is contested, con-
textual, theory-dependent, subjective, personal, rela-
tional, evolving … (e.g. in 2, 9, 43). In contrast, what
filters down to ethics review forms and processes is
often an “impoverished ethics” (Carl Schneider quoted
in Schrag [3], p.3). The shift of power from scholars to
administrators and the rise of a bureaucratic and
self-serving “machine” are lamented. Appeals are made
to trust researchers and their professionalism more and
enable them to take more responsibility for the ethical
decisions they make. Attention is repeatedly drawn to
serious flaws in or lack of relevant definitions, classifica-
tions and boundaries, which have profound impact on
what is being regulated and resulting, for instance, in
journalists conducting (and being praised for) investiga-
tions which social scientists would never be permitted to
do or the state performing observations that are far
more secretive and sinister that any researcher would
ever consider engaging in.
Against this backdrop, the empirical aspect of our
paper is a case study of ethics and governance approvals,
with a focus on quantifying aspects of the process, one
of which does not seem to have been quantified before
(the number of “approvers” involved). Although some of
the findings are striking, we did not have the experience
of a “horror story” or “wounding encounter”. We did not
start an audit because we were frustrated. Our study
arose out of a table we kept in the project Master File to
avoid excessive printing and to justify not printing (com-
munication concerning project approvals must be
printed and stored in a physical Master File). If it were
not for this table, we would not have paid any further at-
tention to the approvals process once we had gone
through it.
This is one of the important points we want to
make: much of the burden of ethics and governance
approvals and the complexity of the system remain
too vague or subliminal to be perceived clearly, like
the underwater part of an iceberg. We fail to change
course in steering ahead, as we can hardly discern
what lies beneath, and we end up damaging the integ-
rity of our research.
Inevitably, by virtue of the position we are taking, as
researchers who have found that, largely unknowingly,
we have been part of a rather inefficient process, our
presentation of issues may feel or be one-sided. We
acknowledge that there are many more sides to the story
that need to be heard before we arrive at a balanced view
of the advantages and disadvantages of current systems.
This is one of them.
Main text
The substantive project (study being approved)
The substantive project whose ethics and governance
approvals we are discussing was a relatively small mixed
methods study, “Prepared to Share?” [1] on patient data
sharing in complex conditions, advanced and progressive
disease and/or at the end of life, conducted by one
Primary Investigator (PI, SB) and one Research Associate
(RA, MP). It was an evaluation of the development,
implementation and outcomes of a local Electronic
Palliative Care Coordination System (EPaCCS) nested in
broader research on attitudes to patient data sharing. As
the EPaCCS service development project was underway
while the study was being carried out, the study was
Petrova and Barclay BMC Medical Ethics            (2019) 20:7 Page 5 of 13
contributing to the EPaCCS project, but the two
remained largely independent. Primary data collection
was carried out between 2013 and 2015 in Cambridge-
shire & Peterborough Clinical Commissioning Group,
England’s second largest CCG. It included:
1) qualitative interviews: 40 with 44 primary
participants – project developers; General
Practitioners (GPs) in their role as data sharing
initiators; data sharing recipients including
palliative care specialists, out-of-hours, hospital
and 111 staff (111 is a non-emergency medical
helpline in England, Scotland and parts of
Wales); patient and carers; key informants from
the local area; and a practice administrator.
(There is a discrepancy between number of inter-
views and participants as some patient and carer
interviews involved more than one person and
the two project leads were interviewed twice;
paper in preparation);
No question touching on end of life care was
included in the interview schedules for patient and
current carers. The focus was fully on data sharing,
although end of life issues were discussed when
raised by interviewees.
2) questionnaire concerning GPs’ and Practice
Managers’ (PMs) familiarity, engagement with and
perceptions of patient data sharing (405 responses,
64% response rate); [66]
3) ethnographic observations, mostly from the process
of developing the data sharing system, but also
from use of the data sharing tools in healthcare
settings;
4) document analysis, using reports, meeting minutes
and email communication of the clinical service
development project.
Three papers have been published from the study,
[66–68] with more in preparation.
While we could have attempted to represent the
study as an evaluation (an exempt category), as its
primary aim was to evaluate a service, we decided
against this course of action. There were vulnerable
individuals in our intended sample, regardless of
how a study is classified relative to a debatable and
often arbitrary distinction. We wanted to benefit
from expert feedback in a full review (as opposed to
a proportionate one) and also ensure that the team
was fully protected, should untoward events occur.
The benefit of saving time was also uncertain.
Exempt studies need a form of approval, be it
minimal, as it is advisable to have them confirmed
exempt through a formal letter (which may be
required by journals before considering
publication). In addition, not going through an
ethics approval would have still meant going
through all other governance approvals, which are
often facilitated and/or expedited if preceded by an
ethics approval.
The project team
As the relative ease or difficulty of going through ethics
and governance approvals is affected by the team
members’ research experience, we are adding a brief
section to that effect. SB is an experienced, inter-
nationally recognised palliative and end of life care
researcher, university lecturer and GP, with all his se-
nior level career in the locality of the study whose
approvals we discuss. MP is a late-early to mid-career
researcher, with some of her education and research
experience strongly ethics-focused (an MA in Philoso-
phy and Ethics of Mental Health, for which she even
wrote coursework on the value of research ethics
committees, and several years of experience on a re-
search programme in “values-based practice” as com-
plementary to evidence-based practice).
The system used for study approval and its relationship
to HRA approval
Study documentation was submitted through the Inte-
grated Research Application System (IRAS), the UK’s
single electronic system for applying for permissions and
approvals for health and social care research. It was
through the Coordinated System for gaining NHS
Permission (CSP), a simplified system available primarily
to studies on the National Institute of Health Research
(NIHR) Portfolio, phased out in March 2016. It is im-
portant to note that the processes we used have now
been modified. Below we present the key claims con-
cerning the changes made. We give the new system the
benefit of the doubt but maintain that it will not resolve
many of the issues we encountered and, under individual
findings, explain why. We also excluded our data on
time delays, as much as they were a substantial con-
cern (including 7 months for National Institute of
Health Research Portfolio application and 7 weeks for
minor ethics amendments). Dealing with delays was
one of the strongest motivators for introducing the
new system and a parameter showing improvements
as a result of it.
The new Health Research Authority (HRA) approval
process for England was rolled out on 11th May 2015.
HRA Approval is represented as a single “radically sim-
plified” approval system for all studies involving the
NHS [69, 70]. At the heart of the reform has been closer
integration of the systems for REC review and NHS
R&D permissions. This would remove the need for
repeated R&D permissions, as granted by each individual
NHS organisation involved in a study. The changes are
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designed to reduce system complexity, timelines and costs;
eliminate duplication; make the UK a more attractive
place for health research and free up of capacity for
research delivery and implementation. [70] In June 2016,
HRA announced a backlog of 3000 amendments [71]
– pending approvals of changes to existing projects.
Bedding-in difficulties can be expected with any sig-
nificant reform and at least the above seem to have
been resolved. A performance report from September
2017 [72] showed that HRA Approval timelines (after
final REC favourable opinion) reduced significantly
between November 2016 to March 2017, after which
they levelled out. The report also stated, however,
that only 14% of the current HRA caseload were
studies actively processed by the HRA team. The
remaining 86% were awaiting other approvals or a re-
sponse from the applicant [op. cit.]. There is some-
thing amiss in a system which controls the outcome
of less than a seventh of its cases.
The approvals audit
This audit-type study arose out of a summary table of
approvals communications maintained for the Master
File of “Prepared to Share?”. Our first recorded commu-
nication about ethics and governance approvals is from
February 2013. The last document was issued in February
2016. (Chronologically, some of the approvals were
granted at a time when HRA Approval was already func-
tional. However, the new system was phased in gradually
and our study was fully approved under the old system.)
During the most intense period of approvals we had no
intention to formalise the emerging evidence, i.e. bias at-
tributable to intentional observations of system ineffi-
ciencies is unlikely. Findings are based on records kept
by the RA (MP) only.
Eighty-nine individuals (a conservative estimate) have been
involved in the study approvals
The study team have communicated with 81 named in-
dividuals for research ethics and governance approval
purposes through email, telephone or in person, with 8
unnamed individuals mentioned in communications as
having provided further advice. These numbers leave out
seven categories of individuals and contributions of
which we are aware, primarily because communication
has been too indirect (such as with staff who processed
criminal records checks) or not strictly required (such as
with gatekeepers who do not have the authority to grant
or withhold permissions formally but could facilitate or
block the study progress in other ways). There are also
individuals involved in the permissions process who
remain invisible to researchers. (In some cases, different
individuals performed the same role, if working as part
of a team or if post-holders changed. However, the same
individual could also perform several roles.)
Thirty-five out of the 44 participants interviewed were
health professionals, decision makers and project devel-
opers and 9 were patients or family members. This
corresponds to roughly two approvers per participant,
with all the necessary caveats added about the mean-
ingfulness of such statistics. In one hospital, 10 indi-
viduals and 101 exchanges outside the supposedly
“one-stop” IRAS platform were needed to interview
4 consultants, a group whose decision-making
capacity is hardly a matter of debate. Table 1 pro-
vides further details of the distribution of individuals
across organisations.
Reducing the involvement of individual NHS sites
would still leave 59 individuals granting formal ap-
provals. Many of those staff whose signatures will no
longer be required will nonetheless be enabling a study’s
conduct at a site – a lesser gatekeeping hurdle to over-
come, but still an important one.
Four hundred and ninety-one exchanges with those
individuals were recorded outside the Integrated Research
Application System (IRAS)
We have recorded 491 exchanges with these 89 individ-
uals, generating 193 pages of email text, excluding at-
tachments. These attachments, whose total volume we
have not quantified, could contain key information (e.g.
amendments requested) or be voluminous (e.g. one of
the first emails we were sent by the local R&D team had
76 pages of attachments; a core set of study documenta-
tion which we have been sending out numbered 78
pages). In theory, the Integrated Research Application
System should act as the platform where all information
necessary for research approvals is requested and pro-
vided. In practice, information not requested in IRAS
forms becomes relevant, especially with non-standard
studies; documents are uploaded on IRAS but are not
accessible to certain groups; or documents are managed
as hard copies and only sent to the study team who then
need to pass them on (REC favourable opinion letters
were a case in point).
While human inefficiencies on both sides will have
had some impact (however we may want to minimise
them through self-serving biases), it will be problem-
atic to explain the full volume of correspondence
external to the IRAS system through the incompe-
tence of its users, whether our or of our colleagues
managing the approvals. We recognise that IRAS is a
living platform undergoing continuous improvement,
but its current version is still largely the same as the
one we used. There is more that an integrated
research application system should enable to deserve
its name.
Petrova and Barclay BMC Medical Ethics            (2019) 20:7 Page 7 of 13
The 31-page IRAS application and key study documentation
appeared to have been read in detail at least 13 times for
one-and-a-half pages of mostly technical suggestions
The 31-page IRAS application and accompanying docu-
mentation have been read in detail at least 13 times – a
conservative estimate based on instances when informed
questions were asked or comments provided (6 REC, 4
local R&D, 2 Sponsor, 1 specific NHS site). We cannot
estimate the number of people who have read specific
sections from the study documents (a typical set con-
sisted of 78 pages and a minimal set of 23 pages). The
total written concerns raised by these 13 people
amounted to just one-and-a-half pages of text and
addressed almost exclusively minor omissions or clarifi-
cations of research procedures. We introduced more
changes to our study documentation as a result of con-
sulting the study Lay User Group than as a result of the
ethics and R&D review processes.
The most significant ethical issues we experienced arose
outside of the NHS ethics committee mandate
The most significant ethical issues we experienced in
conducting the research related to interviews with mem-
bers of the service development team working on the
data sharing system evaluated as part of the study. The
interviews revealed unexpected sources of dissatisfaction
and internal conflict. As both of us are also members of
the service development team, devising informative yet
sensitive ways of feeding back findings was challenging.
There was information we agreed to withhold at this
stage and re-consider for publication in the future, as it
was deemed potentially damaging to team relationships.
It is hard to tell whether the risks of stirring
intragroup conflict could have been picked more effi-
ciently if research on staff were formally reviewed as part
of the NHS ethics review process. Hindsight will often
mislead us in answering such questions. No matter how
thorough an ethics review, it will never be able to cover
the whole complexity, risks and eventualities arising in
the real world. But it is worth noting that NHS ethics
review does not formally consider research on healthcare
professionals and non-NHS staff, even though we were
required to submit information on this aspect of the
study for ethics approval, by virtue of it being part of the
broader project.
The study was often unclassifiable under existing
frameworks, leading to lengthier debates and timeframes
There were four types of classification difficulties associ-
ated with this study which generated protracted and
recurrent discussions and delays: 1) the study had both
research and evaluation aspects; 2) it involved both
patients and health professionals; 3) it combined trad-
itional research and service development elements and
was set both within a University and a healthcare setting;
and 4) it was funded through an open competition in a
geographically confined area, i.e. an open competition
within a closed competition. The decision pathways and
Table 1 Individuals and exchanges involved in the ethics and R&D approvals of the substantive study
Setting/ Type of approval Number of named
individuals from
organisation
Number of recorded
exchanges outside
IRAS
Number of pages of
text generated from
exchanges
Number of
interviewees
Local R&D approval and study assurances, in conjunction
with Clinical Research Network (CRN). Primary outcomes -
decisions on CRN support and approval of access to GP
practices
15 110 63.5 9 patients and carers
14 GP practice staff
NHS Research Ethics Committee (REC) 19 45 9.5 9 patients and carers
Sponsor (University) 17 67 31.5 NA
Research passport No separate
organisation
37a 14.5a NA
Organisation 1 10 101 30.5 4 consultants
Organisation 2 4 78 23.5 3 nurses
Organisation 3, process not completedb 2 12 5 –
Organisation 4, process not completedb 6 27 9.5 –
Organisation 5, process not completedb 2 14 5.5 –
Other (e.g. funder, original employer) 6 included above included above NA
TOTAL 81 491 193 30c
a As the study was associated with a service development project which was not taken up as expected by Organisations 3, 4 and 5, we decided against
conducting interviews with their members of staff. The complexity of R&D approvals was a contributing factor
b Some of the communication was conducted from a now closed institutional email account. We had recorded the contents of exchanges, but had not saved the
emails. As a result, these particular figures are an underestimate
c Patients and carers are included in two boxes, as they were a core concern for two approvals. The remaining 14 interviewees (above the total of 30 in the table)
were not covered by specific rules
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outcomes for the “pure cases”, here combined in a single
study, clashed. For instance, while ‘patients’ and ‘re-
search’ (unless on staff ) necessitate NHS REC approval,
‘evaluation’ and ‘staff ’ are exemption criteria. Or, since
the grant, being primarily for service development, was
held by an NHS-related organisation rather than the
University as a research grant, sponsorship responsibil-
ities could not be attributed unequivocally. Finally, the
research project was funded in two open competitions
within narrow geographical and organisational boundar-
ies. This led to protracted discussions concerning finan-
cial and infrastructure support from the Clinical
Research Network, only available to studies which have
undergone high quality peer review and been funded
through an open competition.
Implications of the findings
Our findings confirm both empirical findings from pre-
vious research on ethics and governance approvals and
impressions which are shared informally amongst many
researchers working in human subjects research. These
concern system complexity, duplication, excessive paper-
work, attention to trivial detail in applications while
missing core ethical issues, and classification difficulties
with significant consequences for the approvals process
and outcomes.
We also suggest two new points. The first is that the
size of the approvals machine and the nature of the work
of its individual parts are largely unknown even to
people who are working in it, including those working to
reform it. Colleagues and reviewers from within the
system have been struck by the figures (as we were) and
even doubtful of our data. This is largely because the
ethics and governance approvals system is a single whole
only by virtue of its outcomes – permissions for a study
to proceed. Other than that, it is at best a collage, at
worst a ‘bag’ of elements belonging to many different
organisations where only some are well connected to
others.
The second point also concerns issues around visibility
and knowability. While many researchers may be experi-
encing ethics and governance approvals processes as
burdensome and time- and resource-consuming, much
of that burden and investment remains under the radar.
As we were moving through the hoops of the approvals
process, we felt we knew how to navigate it, believed we
were managing it well, and found the staff and signator-
ies on the other side unfailingly helpful, even if not
always efficient. Our frustrations were only occasional
and fleeting. We were completely unprepared for some
of the figures generated by the case study. The scale of
the work involved is largely invisible when done piece-
meal. It is worth re-emphasising that the work described
here excludes the core task of obtaining ethics and R&D
approvals – completing the paperwork (such as the
IRAS form) and preparing the accompanying materials
(such as information sheets). Also as mentioned, this
case study was based on records held by the RA only,
document attachments were not counted in, and esti-
mates as a whole were conservative. The impact on the
cost of studies and loss of opportunity to focus on the
substantive research is enormous, even when consider-
ing an incomplete picture.
Steps towards a truly “radically simplified” system
Even though HRA Approvals seems to be achieving
some improvements, we argue that more needs to
change before researchers in England experience the sys-
tem as “radically simplified”. We propose six priority
steps for enabling such change. We believe that these
steps are likely to be generalisable to other contexts, as
many of the challenges they aim to address are shared,
as the literature review has demonstrated. In addition,
our proposals are predicated on flexible and dispersed
working processes, which are becoming increasingly
natural with the growing sophistication of information
technologies.
Support the development of a broad range of customised
research ethics and governance templates rather than rely
on generic, predominantly clinical trials orientated,
templates
Templates for soliciting ethically relevant information
for health research, at least in England, are typically
modelled on templates for clinical trials for investiga-
tional medicinal products (CTIMPs). While screening
questions from other ethically charged areas are also
asked, for instance concerning research on vulnerable
groups (e.g. children, prisoners, individuals lacking men-
tal capacity), utilising human tissue, involving radiation,
etc., these questions are limited. Any health and medical
research involves its particular ethical issues. In our case,
issues around palliative care research, evaluations of
active projects and data sharing received limited or no
attention, not least because the proformas through
which the information was collected were generic. Eth-
ical and regulatory challenges will be far more effectively
captured if templates are customised to different study
types, through endeavours informed by domain experts,
bioethicist and patients.
There are examples of successful introduction of
subject-specific templates for IRBs and their positive
impact [73]. There are also settings where health re-
search informed by the behavioural and social sciences
and the humanities is reviewed by committees within
the respective academic departments, where forms are
likely to be more appropriate. Needs for improving
template relevance are not universal, but sorely needed
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in some contexts. Inevitably, such work will create its
own challenges, most notably template proliferation and
version control. But unless we become more accommo-
dating of the huge variety of studies being conducted,
we will continue to stretch and shrink studies to the
Procrustean bed of CTIMPs.
Improve study classification, particularly in view of the
growing number of innovative and mixed study types
The liminal nature of our study on at least four criteria
(e.g. research – evaluation, study of patients – study of
health professionals, etc.) was a cause of uncertainty and
delays in decisions. To have a system that is equitable and
efficient across study types, we need new and expanded
decision pathways which can accommodate the growing
number of non-typical and multi-method studies.
Possibilities for omissions of ethical and governance
challenges based on typological distinctions should also
be reduced. Currently, service evaluations and NHS
employee research are considered to pose low ethical
risks. This is an oversimplification. Most likely, there are
no essential typological differences between research and
evaluation studies in the ethical challenges they pose.
There are simply lower litigation risks associated with
studies classified as evaluations. Apart from missing
relevant ethical considerations, the current research-
evaluation distinction is a source of unequal treatment
of projects (i.e. when two very similar projects go down
different routes, one of evaluation, the other of research)
and is open to manipulation. Even the most responsible
amongst researchers are tempted to consider if we can
“pass” a study as an evaluation to avoid the complex
NHS approvals process.
Link with associated processes for assessment, feedback,
monitoring and reporting
The ethics and R&D approvals of a study are only one of
the spaces where the methods, design, supporting mate-
rials, staff competence, the adequacy of funding and
other features of a study are reviewed. Funders, the
scientific reviewers whose feedback they solicit, patient
and public involvement (PPI) groups and research
support services often review significantly overlapping,
even the same, documentation. On the monitoring and
reporting side, funders, ethics and R&D officers, univer-
sity administration, impact and pubic engagement offi-
cers, PPI groups also have overlapping needs and
requirements. While the availability of alternatives can
ensure the robustness of the system, creating opportun-
ities to rectify omissions not identified previously, it also
creates wasteful redundancy and duplication of effort.
Better alignment of the work of these different organisa-
tions and networks will lighten up the overall “meta-re-
search burden”, i.e. all those tasks associated with the
research support infrastructure as opposed to the sub-
stantive scholarly work.
Invest in a new generation IT system
If HRA Approval, or any ethics and governance approval
system, strives to be radically more efficient, work on
developing the underpinning IT system should be priori-
tised, with an ambitious vision. Until all study docu-
ments are located in one place and easily searchable,
voluminous email exchanges outside of the system will
continue. Easier access to full study information will
enable de-localising and de-synchronising aspects of the
approvals process that need not be geographically and
temporally fixed. For instance, comments on the ethical
aspects of study protocols or the quality of patient infor-
mation materials may be more efficiently provided by
appropriately qualified but geographically dispersed indi-
viduals rather than a local REC committee. Broader lay
representation will also be facilitated in this way. Apart
from improving efficiently, such broadening of participa-
tion could also enhance the quality of ethical debate.
Furthermore, rather than each PI sending to non-uni-
versity bodies credentials which are identical for every
study within a university (such as insurance documents,
which also periodically expire and are renewed, resulting
in further communication), a university can have “an in-
stitutional legal, ethical and governance profile for re-
search” and access to all of its studies on a shared
system for approvals. Similarly, rather than repeatedly
attaching the same CVs and Good Clinical Practice cer-
tificates, PIs and RAs can have personal “ethical and
governance awareness profiles”, also linking to estab-
lished platforms such as ORCID, ResearchGate, Linke-
dIn or Convey (a platform for conflict of interests
disclosure [74, 75]). Finally, the non-proprietary, non-
sensitive information concerning studies and their
ethical credentials can be made available to the public
through the same system using different (or similar)
viewing rights. Study participants in particular should
have easy access to such documentation and opportun-
ities to report on the ethical conduct and adverse effects
of being in a study.
Enhance system capacity through increasing online
participation and training
One of the reasons for the slow ethics and R&D ap-
provals process is that it is highly localised. In the case
of NHS ethics reviews, this is still focused around an
ethics committee that meets physically to discuss studies
and thus has a limited membership, often worryingly
professionalised, and a high workload. If we broaden the
number of potential participants in the review processes
through a sophisticated IT system and accredited train-
ing, we can dramatically increase the capacity of the
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system. Some possible directions for recruitment efforts
include medical charities and patient groups, whose
involvement in research has been growing steadily in re-
cent years, postgraduate students in ethical disciplines,
and, perhaps most importantly, past research partici-
pants. Involving the latter, however, requires us to step
up efforts to keep participants informed of the outcomes
of studies, recognise their contribution, and nurture
their willingness to support research in a variety of ways.
Perhaps, in the not too distant future, existing Re-
search Ethics Committees will turn into local training
and advice centres, while much larger ethics review
teams do most of the work online.
Encourage researchers to quantify the approvals process
they are going through
Finally, we hope that more colleagues will be willing to
undertake work similar to the one presented here and
that more structural support for bigger and more rigor-
ous studies, as opposed to single case studies, can be
provided by funding bodies. If researchers can offer
evidence concerning ethics and governance approval
processes, rather than primarily express frustration
amongst ourselves, we will have much stronger argu-
ments to insist on radical improvements and better ideas
to enable them.
Conclusions
The broad variety of stakeholders who experience the
impact of burdensome research ethics and governance
approvals processes – researchers, R&D staff, health
professionals involved in research, research participants,
funders, administrators, etc. – have a responsibility to
facilitate and demand substantial improvements of the
system. Unless we contribute to such change, we will
continue to uphold principles of research ethics in a way
which is deeply unethical, by virtue of its wastefulness
on the one hand and impoverished ethics on the other.
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